Feature Type | Standardized | Nominal ANOVA | ||||
---|---|---|---|---|---|---|
mRNA | Cetuximab | GDSC1000 | pan-cancer | AAC | 0.36 | 7e-19 |
mRNA | Erlotinib | CTRPv2 | pan-cancer | AAC | 0.3 | 3e-16 |
mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.32 | 1e-15 |
mRNA | Erlotinib | gCSI | pan-cancer | AAC | 0.53 | 4e-13 |
mRNA | Erlotinib | CCLE | pan-cancer | AAC | 0.42 | 2e-12 |
mRNA | Gefitinib | CTRPv2 | pan-cancer | AAC | 0.25 | 5e-11 |
mRNA | canertinib | CTRPv2 | pan-cancer | AAC | 0.24 | 3e-10 |
mRNA | BIBW2992 | CTRPv2 | pan-cancer | AAC | 0.23 | 4e-09 |
mRNA | Panobinostat | CCLE | pan-cancer | AAC | -0.3 | 3e-08 |
mRNA | Vandetanib | CTRPv2 | pan-cancer | AAC | 0.21 | 3e-08 |